Immune cell triads reprogram exhausted CD8 + T cells for effective tumor elimination.

In this issue of Cancer Cell, Espinosa-Carrasco et al. show that the efficacy of cancer immunotherapies depends upon the formation of intratumoral immune triads between antigen-presenting cells and antigen-specific CD4 ⁺ and CD8 ⁺ T cells. This interaction reprograms tumor-specific CD8 ⁺ T cells to exert potent effector functions and eradicate established solid tumors.
Competing Interests: Declaration of interests E.L. received research grants from Bristol Myers Squibb on a topic unrelated to this paper, royalties from the NIH for a patent on methods to develop T memory stem cells, and consulting fees from BD Biosciences, Biolegend, Swarm Therapeutics, Menarini, Amgen, and Pfizer.
(Copyright © 2024 Elsevier Inc. All rights reserved.)